18.45 - 19.45

Who benefits most from an early combination treatment approach in type 2 diabetes?

Evening Session

Matthias Blüher
Welcome and introduction
Matthias Blüher
Clinical inertia and treatment intensification
Helmut Brath
VERIFY results in the context of disease pathogenesis
Juliana Chan
Early combination treatment in practice
Q&A panel discussion
Matthias Blüher
Closing remarks
Symposium by:
Novartis Pharma AG